Stocksigma LogoStocksigma Logo

Aarti Pharmalabs Reports Strong Q2 FY27 Operating Performance and Expansion Plans

Aarti Pharmalabs delivered strong Q2 FY27 consolidated operational revenue of INR 6,105 Mn (up 45.9% YoY, 13.9% QoQ), with EBITDA surging 80.2% YoY to INR

Aarti Pharmalabs Reports Strong Q2 FY27 Operating Performance and Expansion Plans

Aarti Pharmalabs Ltd · Investor Presentation · 29 Oct 2026, 7:00 pm

Aarti Pharmalabs Reports Strong Q2 FY27 Operating Performance and Expansion Plans Aarti Pharmalabs delivered strong Q2 FY27 consolidated operational revenue of INR 6,105 Mn (up 45.9% YoY, 13.9% QoQ), with EBITDA surging 80.2% YoY to INR 1,346 Mn and PAT rising 248.8% YoY to INR 715 Mn. Xanthine Derivatives contributed 50% of revenue, followed by API/Intermediates at 30% and CDMO/CMO at 13%. The firm is investing INR 149 Cr in Atali Block 2 (~405 KL) for CDMO, targeting commercialization by H2 FY28, while guiding for a 15–18% revenue and EBITDA CAGR over 3–4 years.

Original exchange filing (PDF)

More announcements from Aarti Pharmalabs Ltd

All Aarti Pharmalabs Ltd announcements